可溶性 Fms 样酪氨酸激酶-1 与慢性肾脏病患者的动脉粥样硬化。
Soluble fms-like tyrosine kinase-1 and atherosclerosis in chronic kidney disease.
机构信息
1] Experimental and Clinical Research Center, Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany [2] Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
出版信息
Kidney Int. 2014 Feb;85(2):238-40. doi: 10.1038/ki.2013.402.
Vascular endothelial growth factor (VEGF) and its cousins, such as placental growth factor, have moved into the daily clinical arena. One-step-removed regulators, such as the VEGF splice variant soluble fms-like tyrosine kinase-1 (sFlt-1), now clinically emerge. sFlt-1 keeps our corneas 'clean.' However, sFlt-1 could also cause disease, such as preeclampsia. The report by Matsui et al. on ApoE and sFlt-1 gene-deleted mice could foster important subsequent research. We are limited only by our imaginations.
血管内皮生长因子 (VEGF) 及其类似物，如胎盘生长因子，已经进入了日常临床领域。一步到位的调节剂，如 VEGF 剪接变体可溶性 Fms 样酪氨酸激酶-1（sFlt-1），现在也出现在临床上。sFlt-1 使我们的角膜保持“清洁”。然而，sFlt-1 也可能导致疾病，如先兆子痫。Matsui 等人关于载脂蛋白 E 和 sFlt-1 基因缺失小鼠的报告可能会推动重要的后续研究。我们的想象力有限。
Zotero 插件